FILE PHOTO: Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi/File Photo
NEW DELHI (Reuters) - India is struggling to convince its health and front-line workers to take a homegrown COVID-19 vaccine controversially approved without late-stage efficacy data, government data showed https://dashboard.cowin.gov.in on Thursday, days ahead of a wider roll-out.
The country has the world's second-highest number of COVID-19 infections after the United States, with cases recently surging as mask wearing declines and states have eased social distancing measures. A lack of confidence in a homegrown vaccine country could prevent India from meeting its target of vaccinating 300 million of its 1.35 billion people by August.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
